+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Hereditary Angioedema (HAE) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767315
  • Report
  • April 2019
  • Region: Global
  • 83 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • CSL Ltd
  • Ionis Pharmaceuticals Inc
  • Pharming Group NV
  • Quotient Clinical Ltd
  • Shire Plc
  • MORE
The global clinical trial report- “2019 Hereditary Angioedema (HAE) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Hereditary Angioedema (HAE). It presents in-depth analysis of Hereditary Angioedema (HAE) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Hereditary Angioedema (HAE).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Hereditary Angioedema (HAE) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Hereditary Angioedema (HAE)

The research work is prepared through extensive and continuous research on Hereditary Angioedema (HAE) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Hereditary Angioedema (HAE) patients are identified
  • The report includes panorama of Hereditary Angioedema (HAE) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Hereditary Angioedema (HAE) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CSL Ltd
  • Ionis Pharmaceuticals Inc
  • Pharming Group NV
  • Quotient Clinical Ltd
  • Shire Plc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Hereditary Angioedema (HAE) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Hereditary Angioedema (HAE) Clinical Trials by Region
2.2.2 Average Enrollment of Hereditary Angioedema (HAE) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Hereditary Angioedema (HAE) Treatment, 2019

3. Region wise Hereditary Angioedema (HAE) Clinical Trials
3.1 Asia Pacific Hereditary Angioedema (HAE) Clinical Trials by Country
3.2 Europe Hereditary Angioedema (HAE) Clinical Trials by Country
3.3 North America Hereditary Angioedema (HAE) Clinical Trials by Country
3.4 Middle East and Africa Hereditary Angioedema (HAE) Clinical Trials by Country
3.5 South and Central America Hereditary Angioedema (HAE) Clinical Trials by Country

4. Hereditary Angioedema (HAE) Clinical Trial Trends
4.1 Start Year wise Hereditary Angioedema (HAE) Clinical Trials
4.2 Phase wise Hereditary Angioedema (HAE) Clinical Trials
4.3 Trial Status wise Hereditary Angioedema (HAE) Clinical Trials
4.4 Trial Type wise Hereditary Angioedema (HAE) Clinical Trials

5. Hereditary Angioedema (HAE) Average Enrollment Trends
5.1 Average Enrollment in Hereditary Angioedema (HAE) Trials by Year
5.2 Average Enrollment in Hereditary Angioedema (HAE) Trials by Phase
5.3 Average Enrollment in Hereditary Angioedema (HAE) Trials by Status
5.4 Average Enrollment in Hereditary Angioedema (HAE) Trials by Type of Trial

6. Companies Participating in Hereditary Angioedema (HAE) Clinical Trials
6.1 Hereditary Angioedema (HAE) Trials by Sponsor Type
6.2 Hereditary Angioedema (HAE) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Hereditary Angioedema (HAE) Trials- Phase 1
7.2 Hereditary Angioedema (HAE) Trials- Phase 2
7.3 Hereditary Angioedema (HAE) Trials- Phase 3
7.4 Hereditary Angioedema (HAE) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Hereditary Angioedema (HAE) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Figure 7: North America - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Figure 9: Hereditary Angioedema (HAE) Clinical Trials by Phase
Figure 10: Hereditary Angioedema (HAE) Clinical Trials by Trial Status
Figure 11: Hereditary Angioedema (HAE) Clinical Trials by Type
Figure 12: Hereditary Angioedema (HAE) Clinical Trials by Sponsor Type
Figure 13: Hereditary Angioedema (HAE) Clinical Trials by Leading Sponsors
Figure 14: Hereditary Angioedema (HAE) Average Enrollment by Phase
Figure 15: Hereditary Angioedema (HAE) Average Enrollment by Trial Status
Figure 16: Hereditary Angioedema (HAE) Average Enrollment by Type
Figure 17: Hereditary Angioedema (HAE)- Average Enrolment by Type of Sponsors
Figure 18: Hereditary Angioedema (HAE)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Hereditary Angioedema (HAE) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Table 5: Europe - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Table 7: North America - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Hereditary Angioedema (HAE) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Hereditary Angioedema (HAE) Average Enrollment by Phase
Table 15: Hereditary Angioedema (HAE) Average Enrollment by Trial Status
Table 16: Hereditary Angioedema (HAE) Average Enrollment by Type
Table 17: Hereditary Angioedema (HAE)- Average Enrolment by Type of Sponsors
Table 18: Hereditary Angioedema (HAE)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • Advanced Medical Services GmbH
  • Atlantic Research Group Inc
  • BioCryst Pharmaceuticals Inc
  • CSL Ltd
  • Ionis Pharmaceuticals Inc
  • Kalvista Pharmaceuticals Inc
  • Parexel International Corp
  • Pharming Group NV
  • Quotient Clinical Ltd
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll